# Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

> **NCT03451331** · PHASE2 · COMPLETED · sponsor: **Matthew Galsky** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03451331
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-10
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-07-28
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451331, "Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03451331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*